

CONCLUSION

Independent and Publicly
Funded Research: A New
Global Model



Dr G S Bhattacharya

India



Member DCTF -ESMO



Delivering Healthcare Solutions

- **Advancing and simplifying treatment**
 - Identifying new molecules with enhanced efficacy
 - Medications with once-daily dosing, fewer side effects
 - Partnering with academia
- **Conducting and supporting clinical research**
 - Optimizing treatment strategies
 - Developing prevention
 - Partnering with government institutions
- **Making treatment available**
 - Tiered pricing and multinational access initiatives
 - Lowering production costs
- **Educating and influencing others**

Sources of funds

- ***Direct transfer***
of contracts, grants or donations and may take the form of money or other resource
- government funds
- procurement of R&D,
- performers of R&D
- ***INDUSTRY FUNDING***
 - Pharmaceutical Industry
 - Biotechnology Industry
- ***FOUNDATIONS***
 - independent endowments and funds,
 - corporate giving foundations
 - community-based donors
- ***VOLUNTARY HEALTH ORGANIZATIONS***
- ***INDIVIDUAL GIFTS AND BEQUESTS***

Collaborative Partnership

- Develop partnerships with researchers, makers of health policies, and the community.
- Involve partners in sharing responsibilities for determining the importance of health problem, assessing the value of research, planning, conducting, and overseeing research, and integrating research into the health-care system.
- Respect the community's values, culture, traditions, and social practices.
- Develop the capacity for researchers, makers of health policies, and the community to become full and equal partners in the research enterprise.
- Ensure that recruited participants and communities receive benefits from the conduct and results of research.
- Share fairly financial and other rewards of the research.


Social value

- Specify the beneficiaries of the research—**who**.
- Assess the importance of the health problems being investigated and the prospective value of the research for each of the beneficiaries—**what**.
- Enhance the value of the research for each of the beneficiaries through dissemination of knowledge, product development, long-term research collaboration, and/or health system improvements. **How**
- Prevent supplanting the extant health system infrastructure and services.

Scientific validity

- Ensure that the scientific design of the research realizes social value for the **primary beneficiaries of the research**.
- Ensure that the scientific design realizes the scientific objectives while guaranteeing research participants the **health-care interventions to which they are entitled**.
- Ensure that the research study is feasible within the social, political, and cultural context or with sustainable improvements in the local health-care and physical infrastructure.

The International Development “Assistance Octangle”



Within the Octangle

- Every dyad and triad is subject to motivational, informational, and power problems
- Many participants want short-term benefits
- *Lack of effective counteracting institutions (may even exacerbate problems)*
- A failure at any one node of the Octangle likely to lead to major problems – very little self-correction in the system as a whole

Lessons from the Octangle

- Many stakeholders – no effective ownership
- Institutional incentives as important, or more, than size of financial investment
- Incentives facing consultants need careful consideration
- Beneficiaries are important stakeholders, but frequently no voice and little power

Strengths & Weaknesses:

Strengths:


- Renewed ND R&D
 - It is working
- Affordability & adaptedness as central criteria for new products
- Harnessing private sector capacity for public ends (CSR)
- Light networked structure
- Global coordination of scarce investments

Weaknesses:

- Untested institutional model: will it work?
- Financial sustainability unclear
- Governance unclear (accountability, decision-making, transparency)
- Developing country participation is limited
- Risk that private interests undermine public goals
- Limited to ND (diseases without a market)

Sources: Kettler & Towse (2001), Ziemba (2005), Moran et al. (2005), Widdus (various), Buse (various), Turner & Makgoba (2008), Moon (forthcoming)

Fund for R&D in diseases



OF COURSE IF IT WEREN'T FOR THE SUPPORT OF MY DEAR,
DEAR FRIENDS I WOULDN'T BE WHERE I AM TODAY!



